Targeted NGS Service

NGS Gene Panel Specifically Detects Actionable Mutations for Targeted Therapy

Minimum of three samples required

Covers 65 genes including major oncogenes and tumor suppressor genes

Less than 7-day turnaround time from FFPE/plasma sample to reporting

Cost-effective service with high quality testing and reliable results

Highly sensitive: as low as 1% variant allele frequency (VAF) detection

Low DNA input: 10ng for detection of somatic mutations

OptiSeq™ NGS Pan-Cancer Panel Service

A targeted cancer panel, especially an actionable gene panel, provide reference information and guidance for cancer therapies. Our pan-cancer gene panel includes sequencing information for more than 600 amplicons in 65 common oncogenes and tumor suppressor genes and identifies gene mutations with clinical significance under both research and CLIA lab environment.

OptiSeq™ Pan-Cancer Gene Panel (65 Genes)

ABL1AKT1ALKAPCATMBRAFBRCA1
BRCA2CDH1CDKN2ACSF1RCTNNB1DDR2DNMT3A
EGFRERBB2ERBB3ERBB4EZH2FBXW7FGFR1
FGFR2FGFR3FLT3FOXL2GNA11GNAQGNAS
HNF1AHRASIDH1IDH2JAK2JAK3KDR
KITKRASMAP2K1METMLH1MPLMSH6
MTORNF1NF2NOTCH1NPM1NRASPDGFRA
PIK3CAPIK3R1PTCH1PTENPTPN11RB1RET
SMAD4SMARCB1SMOSRCSTK11TERTTP53
TSC1VHL

Need Help?

Call us: +1 (800) 246-8878

Email us: information@diacarta.com

Contact Us!

Ready to Subscribe and Learn?

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X